Stem Cell Theranostics, Inc. (SCT) is a Silicon Valley technology company dedicated to revolutionizing the future treatment of heart disease through the use of pluripotent stem cells. Heart disease is the leading cause of death and illness in the Western World, and is responsible for over 600,000 deaths per year in the US alone. Our "disease in a dish" and "clinical trial in a dish" platforms are currently in use for development of cardiovascular drugs as well as safety tests of non-cardiac drugs for cardiotoxicity.
SCT is collaborating with partners for cardiovascular drug discovery and toxicity screening using patient-specific "disease in a dish" models. We currently have both academic and commercial clients.